Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $109,101.06 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 6,471 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $109,101.06. Following the sale, the insider now owns 54,322 shares in the company, valued at $915,868.92. This trade represents a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Centessa Pharmaceuticals Stock Up 3.5 %

Centessa Pharmaceuticals stock opened at $17.84 on Friday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a 1-year low of $7.38 and a 1-year high of $18.97. The company has a fifty day simple moving average of $16.74 and a 200 day simple moving average of $15.30. The company has a market cap of $2.35 billion, a P/E ratio of -11.66 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on CNTA shares. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim increased their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $25.83.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CNTA. Jane Street Group LLC acquired a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $2,834,000. Wellington Management Group LLP bought a new stake in Centessa Pharmaceuticals during the third quarter worth $1,609,000. State Street Corp acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $777,000. Ally Bridge Group NY LLC bought a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at about $4,951,000. Finally, GSA Capital Partners LLP increased its stake in shares of Centessa Pharmaceuticals by 66.1% during the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after purchasing an additional 37,275 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.